What are ASP Isotopes' key commercial and operational milestones targeted for 2026, according to the update?

ASP Isotopes announced intentions to achieve first commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 isotopes in 2026, and to reach Helium Phase 1 nameplate capacity in Q3 2026.

What were ASP Isotopes' financial highlights as of December 31, 2025, including cash position, 2025 revenue, net loss, and capital raised?

As of December 31, 2025, ASP Isotopes held $333 million in cash and equivalents; reported $5.7 million in product revenue for 2025; incurred a net loss of $175.1 million for 2025; and had raised over $345 million in capital.

$333M Cash Backs ASP Isotopes' 2026 Push for First Sales

Apr 13, 2026

ASP Isotopes announced plans for its first commercial isotope shipments in 2026, backed by $333 million in cash reserves. The company aims to achieve Helium Phase 1 nameplate capacity by Q3 2026 while targeting over $300 million EBITDA by 2031.

Stock Titan

ASP Isotopes Provides 2026 Business Update; $333M Cash, Helium Phase 1 Capacity Expected Q3 2026

TradingView — Track All Markets

$333M Cash Backs ASP Isotopes' 2026 Push for First Sales

FAQ